210366-15-7

Basic information

• Product Name: 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-1-(phenylMethoxy)-
• Synonyms: 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-1-(phenylMethoxy)-;1-(Benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid;1,6-dihydro-6-oxo-1-(phenylMethoxy)-2-Pyridinecarboxylic acid
• CAS NO: 210366-15-7
• Molecular Formula: C₁₃H₁₁NO₄
• Molecular Weight: 245.23074
• Product Categories: Heterocycle-Pyridine series
• Mol File: 210366-15-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 176-177 °C
• Boiling Point: 403.349 °C at 760 mmHg
• Flash Point: 197.739 °C
• Appearance: /
• Density: 1.384 g/cm³
• Storage Temp.: 2-8°C
• PKA: 3.98±0.20(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-1-(phenylMethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-1-(phenylMethoxy)-(210366-15-7)
• EPA Substance Registry System: 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-1-(phenylMethoxy)-(210366-15-7)

Safety Data

• Hazardous Substances Data: 210366-15-7(Hazardous Substances Data)

Usage

General Description

2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-1-(phenylMethoxy)- is a chemical compound with the molecular formula C13H11NO4. It is a derivative of pyridinecarboxylic acid with a phenylmethoxy group attached to the 1 position and a 1,6-dihydro-6-oxo group. 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-1-(phenylMethoxy)- has potential pharmacological properties and has been studied for its potential use in the treatment of various diseases. It may also have applications in organic synthesis and drug development. Further research is needed to fully understand the properties and potential uses of this chemical compound.

Upstream product

• 210366-13-5 methyl 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylate 
• 100-44-7 benzyl chloride 
• 94781-89-2 1,2-dihydro-1-hydroxy-2-oxopyridine-6-carboxylic acid 
• 19621-92-2 6-Hydroxypicolinic acid 
• 210366-10-2 methyl-1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxylate 
• 1094194-45-2 6-carboxy-1,2-HOPO 
• 94781-88-1 6-bromopyridine-2-carboxylic acid-1-N-oxide 
• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 100-39-0 benzyl bromide 
• 19621-92-2 2-oxo-1,2-dihydropyridine-6-carboxylic acid 

Downstream Products

• 210366-17-9 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid chloride 
• 770738-07-3 1-(benzyloxy)-6-(2-thioxothiazolidine-3-carbonyl)pyridin-2(1H)-one 
• 910106-57-9 5LIO-1,2-HOPOBn 
• 460986-08-7 3,4,3-LI-(1,2-HOPOBn) 
• 460986-10-1 3,4,3-LI-(1,2-Me-3,2-HOPO)Bn 
• 1297532-40-1 TAM(o-phen-1,2-HOPO)2(Bn)4 
• 1297532-42-3 TAM(o-phen-1,2-HOPO)2 
• 210366-13-5 methyl 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylate 

Relevant articles and documents

Alternative chelator for 89Zr radiopharmaceuticals: Radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO)

Zirconium-89 is an effective radionuclide for antibody-based positron emission tomography (PET) imaging because its physical half-life (78.41 h) matches the biological half-life of IgG antibodies. Desferrioxamine (DFO) is currently the preferred chelator for 89Zr4+; however, accumulation of 89Zr in the bones of mice suggests that 89Zr4+ is released from DFO in vivo. An improved chelator for 89Zr4+ could eliminate the release of osteophilic 89Zr4+ and lead to a safer PET tracer with reduced background radiation dose. Herein, we present an octadentate chelator 3,4,3-(LI-1,2-HOPO) (or HOPO) as a potentially superior alternative to DFO. The HOPO ligand formed a 1:1 Zr-HOPO complex that was evaluated experimentally and theoretically. The stability of 89Zr-HOPO matched or surpassed that of 89Zr-DFO in every experiment. In healthy mice, 89Zr-HOPO cleared the body rapidly with no signs of demetalation. Ultimately, HOPO has the potential to replace DFO as the chelator of choice for 89Zr-based PET imaging agents.

Synthesis and iron chelating properties of hydroxypyridinone and hydroxypyranone hexadentate ligands

Chelation therapy has become an important therapeutic approach for some diseases. In attempt to identify clinically useful chelators, four hexadentate ligands were synthesized by conjugating the corresponding bidentate ligands (3-hydroxypyridin-4-one (3,4-HOPO), 3-hydroxypyridin-2-one (3,2-HOPO), 1-hydroxypyridin-2-one (1,2-HOPO), and 3-hydroxypyran-4-one) each with a free amino group to a tripodal acid. Their pKa values and affinities for iron(iii) were investigated. The pFe3+ values of the hexadentate pyridinones 1 (3,4-HOPO), 3 (3,2-HOPO) and 4 (1,2-HOPO), and the pyranone 2 was found to follow the sequence 1 > 4 ? 3 > 2, which is different to the pFe3+ value sequence of the corresponding bidentate forms (3,4-HOPO ? 3,2-HOPO > 1,2-HOPO > 3-hydroxypyranone). Hexadentate 3,4-HOPOs and 1,2-HOPOs have the greatest potential as iron scavenging agents.

New insights into structure and luminescence of EuIII and SmIII complexes of the 3,4,3-LI(1,2-HOPO) ligand

We report the preparation and new insight into photophysical properties of luminescent hydroxypyridonate complexes [MIIIL]- (M = Eu or Sm) of the versatile 3,4,3-LI(1,2-HOPO) ligand (L). We report the crystal structure of this ligand